Chapter 514: Chapter 292: Public Live Broadcast of an Ultra-Difficult Surgery! What Confidence (2)
It would become the discipline within cardiac surgery most worthy of promotion and research for the next decade.
The various department directors also began to carefully review the patient’s case.
Due to the complexity of the patient’s condition, the directors of cardiology, hepatic tumor surgery, and radiology had also been invited to participate in the discussion.
Hu Zhipeng had the honor of accompanying Director Ren to participate in the surgical consultation, serving as part of his clinical practice before the Asia-Pacific Region Cardiac Surgery Competition.
Being several rungs down the ladder from Wu Ting, Hu Zhipeng was tasked with reading the case file and distributing materials.
"...Esteemed leaders, directors, and international experts, the patient’s condition is, in summary, as follows:"
"The ECG shows: Sinus rhythm, high left ventricular voltage, ST-segment depression, and flat or inverted T-waves in leads I, aVL, II, III, aVF, and V4 through V6..."
"The transthoracic echocardiogram shows: A calcified aortic valve with mild stenosis and severe regurgitation; thickening of the interventricular septum and left ventricular wall; and impaired left ventricular diastolic function..."
"The coronary CT angiography reveals: A right dominant circulation and three-vessel coronary atherosclerosis. There is mixed calcified plaque in the wall of the left main artery, with partial moderate to severe stenosis of approximately 50-80%. The proximal-to-mid left anterior descending artery and its first diagonal branch show partial mild stenosis of approximately 20-30%. Multiple calcified plaques are visible in the circumflex artery, with no significant stenosis. The right coronary artery shows multiple mixed calcified plaques in various segments, with partial mild to moderate stenosis of 30-60%..."
Listening to Hu Zhipeng’s report, everyone was once again struck by the complexity of the patient’s condition.
For an ordinary patient, even if the lesion is in a hidden location, it’s still confined to one area—like a single landmine buried on a road.
Hao Lijuan’s situation, however, was like a road completely covered in landmines. A conventional surgical approach would be absolutely out of the question.
In addition, Hao Lijuan also had liver cancer. While comprehensive treatment at the MD Anderson Cancer Center had stabilized her condition in the short term, it had now staged a dangerous rebound in combination with her various cardiovascular complications!
The director of Hepatic Tumor Surgery also explained Hao Lijuan’s liver condition, which had entered a late-stage, rapidly progressing phase.
"To the experts in cardiac surgery, I’m not very familiar with cardiovascular issues. But regarding her liver cancer, the patient has already missed the window for surgical intervention. And due to her cardiovascular complications, she certainly cannot undergo conventional treatments like radiotherapy again."
"I think it’s very difficult... It’s possible we can only provide conservative, end-of-life palliative care to give her some final dignity and a slightly better quality of life."
Hearing the words of the director of the Fuwai Liver Tumor Surgery Department, everyone fell silent.
Dean James, however, was already mentally prepared for this. It was the same conclusion reached by the hepatic tumor surgery experts he had previously invited for a consultation.
Scholar Jiang looked toward Wu Ting.
"Director Wu, I recall you used to specialize in the field of liver oncology. You even competed directly with the MD Anderson Cancer Center. Do you have any thoughts?"
Some of the directors who weren’t aware that Wu Ting was also an expert in hepatic tumor surgery looked at him with a mixture of anticipation and admiration.
Wu Ting carefully reviewed the patient’s case. With his Grandmaster of Hybrid Technology (Red) status and his full skill tree in liver oncology (Black), he could actually see a path to survival amid this desperate situation.
"Directors, Scholar Jiang, Dean James, Professor Livingston, I do actually have some ideas. Please allow me to analyze them in detail."
"First, one thing is certain: the patient’s time is running out. Treating either the liver cancer or the cardiovascular disease alone will not be enough to bring her back from the brink."
"Therefore, we must currently implement a combined Hybrid multidisciplinary treatment plan that incorporates liver cancer therapy."
"For this patient, I plan to combine her liver cancer treatment and cardiovascular treatment into a single, simultaneous operation."
"Regarding the field of liver cancer—which many of the directors here may not be familiar with—my team and I have already been conducting clinical trials on a systemic radical cure for liver cancer. For Hao Lijuan, we can effectively treat her using the second and third stages of this therapy, which involve immune checkpoint inhibitor therapy, antiviral therapy, and transcatheter arterial chemoembolization."
"As for the patient’s cardiovascular diseases, I have a complete and mature set of Hybrid therapies. By using off-pump coronary artery bypass grafting, combined with aortic valve replacement and endovascular repair, we can ultimately treat all related conditions."
"And the treatments for these two fields can be perfectly integrated."
To ensure all the experts, Dean James, Professor Livingston, and Scholar Jiang could see clearly, Wu Ting took out a marker and began to draw on the conference room’s whiteboard.
"You all might not be very familiar with liver cancer treatment, but its concepts and surgical procedures have a high degree of overlap with our cardiovascular field."
"First, the immune checkpoint inhibitor therapy also requires a form of extracorporeal circulation. This can be combined with the beating-heart technique, allowing both to be performed at the same time..."
"Second, the transcatheter arterial chemoembolization and the cardiovascular interventional therapy via the femoral artery can be perfectly optimized and integrated. Combining two interventions into one operation can completely avoid the complications and potential risks of multiple surgeries..."
As everyone listened to Wu Ting’s detailed explanation, their eyes lit up.
Indeed, these two treatment plans, which seemed to belong to completely different systems, blended together perfectly.
And the absolute core of this operation, aside from Wu Ting’s Hybrid Technology concept, were the indispensable tools he himself had developed: the fourth-generation bioresorbable polymer vascular stent, the adjustable self-expanding delivery system, and the 3D image guidance system for the liver cancer field.
If you find any errors ( broken links, non-standard content, etc.. ), Please let us know < report chapter > so we can fix it as soon as possible.